<DOC>
	<DOCNO>NCT01746836</DOCNO>
	<brief_summary>The goal clinical research study learn ponatinib help control CML chronic phase . The safety drug also study . Ponatinib design block function BCR-ABL , abnormal protein responsible cause CML . This may cause cancer cell die . Ponatinib may cause blood clot form artery vein . Depending location clot , could cause heart attack , stroke , severe damage tissue , death . A blood clot may occur within 2 week start take drug . About 25 % ( 1 4 ) patient take drug form abnormal clot . Blood clot occur patient know risk factor form clot . If develop blood clot , need stop take ponatinib . In case , emergency surgery could need remove clot restore blood flow .</brief_summary>
	<brief_title>Ponatinib Second Line Therapy Patients With Chronic Myeloid Leukemia Chronic Phase Resistant Intolerant Imatinib , Dasatinib Nilotinib</brief_title>
	<detailed_description>Study Drug Administration : You take ponatinib mouth 1 time every day study cup ( 8 ounce ) water . You may take ponatinib without food . If vomit dose , take ponatinib make dose . You wait next schedule dose . You complete study diary record date time take study drug time . If miss dos , also note study diary . You bring diary every study visit . Study Visits : The study staff help schedule study visit . The following test procedure perform : - Blood ( 1/2 tablespoon time ) drawn routine test every 1-2 week first 4 week , every 4-6 week first year , every 3-4 month second year , every 4-6 month . These test do home doctor send study doctor . - You EKG every 3 month first year . - You physical exam ask drug may take side effect may every 3 month first year , every 6-12 month . - Blood ( 2 teaspoon ) draw check status disease every 3-4 month first year , every 6-12 . - You bone marrow aspirate genetic test check status disease every 3-4 month first year , every 6-12 month next 2 year , every 2-3 year . Length Study : You may take study drug 5 year . You take study early intolerable side effect occur , disease get bad , unable follow study direction . Your participation study complete follow-up visit/call ( describe ) . If disease get bad disease never respond treatment ponatinib , blood ( 1 tablespoon ) draw 30 day last dose ponatinib check change BCR-ABL protein may explain response study drug . Follow-Up : Within 30 day leave study , call come clinic learn side effect symptom may . If call , call last 2-3 minute . This investigational study . Ponatinib FDA approve treat patient certain type leukemia . Its use study investigational . Up 50 participant enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Diagnosis Phpositive ( cytogenetics FISH ) BCRABLpositive ( PCR ) CML chronic phase . 2 . Patients demonstrated failure therapy one FDAapproved TKI ( currently imatinib , dasatinib , nilotinib approve frontline therapy ) , define per European leukemiaNet ( ELN ) recommendation : 1 . Less complete hematologic response ( CHR ) beyond 3 month ; 2 . No cytogenetic response beyond 6 month ; 3 . Less PCyR ( Ph+ &gt; 35 % ) beyond 12 month ; 4 . Less CCyR beyond 18 month ; 5 . Loss response development mutation clonal chromosomal abnormality time TKI treatment ; 6 . Intolerance imatinib , dasatinib nilotinib define grade 3 4 toxicity , persistent grade 2 toxicity despite optimal management include dose adjustment , patient dose reduction consider patient best interest obtain maintain adequate response . Intolerant patient achieve lost major cytogenetic response time enrollment . 3 . Age &gt; /= 18 year . 4 . ECOG performance 02 . 5 . Adequate end organ function , define follow : total bilirubin &lt; /= 1.5x ULN ( unless due Gilbert syndrome , case &lt; /= 3.0x ULN ) , SGPT &lt; /= 2.5x ULN , creatinine &lt; /=1.5x ULN . 6 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 7 . Reliable telephone access receive call interactive voice response system ( IVR ) ( applicable patient participate optional symptom burden assessment ) . 8 . Women pregnancy potential must practice effective method birth control course study , manner risk failure minimize : 1 . Prior study enrollment , woman childbearing potential ( WOCBP ) must advise importance avoid pregnancy trial participation &amp; potential risk factor unintentional pregnancy ; 2 . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ; 3 . In addition , men enrol study understand risk sexual partner childbearing potential &amp; practice effective method birth control ; 4 . Women &amp; men must continue birth control duration trial &amp; least 3 month last dose study drug ; 9 . **continued : 5 . All WOCBP MUST negative pregnancy test prior first receive investigational product . 10 . Patients discontinue therapy imatinib , dasatinib nilotinib antileukemia therapy ( except hydroxyurea ) , least 48 hour prior start study therapy recover toxicity due therapy least grade 1 . The use hydroxyurea allow immediately prior study entry . 1 . Prior therapy BCRABLtargeted TKIs except imatinib , dasatinib nilotinib ( e.g. , bosutinib ) . 2 . NYHA cardiac class 34 heart disease . 3 . Cardiac Symptoms : Patients meet follow criterion eligible : History unstable angina , myocardial infarction , TIA , stroke , peripheral arterial occlusive disease , venous thromboembolism pulmonary embolism ; Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; Prolonged QTc interval preentry electrocardiogram ( &gt; 470 msec ) Fridericia Bazett 's correction ; Congestive heart failure ( NYHA Class III IV ) within 3 month prior first dose ponatinib . 4 . Patients active , uncontrolled psychiatric disorder include : psychosis , major depression , bipolar disorder . 5 . Patients uncontrolled hypertension ( define sustain systolic blood pressure &gt; 160 mmHg diastolic &gt; 100 mmHg ) . 6 . Pregnant breastfeed woman exclude . 7 . Patients history pancreatitis . 8 . Patients accelerate blast phase , patient ever document blast phase CML , exclude . The definition exclude CML phase follow : a. Blastic phase : presence 30 % blast peripheral blood bone marrow ; b . Accelerated phase CML : presence follow feature : Peripheral marrow blast 15 % ; Peripheral marrow basophils 20 % ; Thrombocytopenia &lt; 100 x 10 ( 9 ) /L unrelated therapy ; Documented extramedullary blastic disease outside liver spleen ; c. Clonal evolution define presence additional chromosomal abnormality Ph chromosome historically include criterion accelerate phase . 9 . **continued : However , patient clonal evolution criterion accelerate phase significantly good prognosis . Thus , patient clonal evolution criterion accelerate phase eligible study , analyze separately . 10 . Patients receive one FDAapproved TKI CML , investigational , nonFDA approve TKI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Imatinib-resistant intolerant</keyword>
	<keyword>Imatinib failure</keyword>
	<keyword>Ph-positive ( cytogenetics FISH )</keyword>
	<keyword>BCR-ABL-positive ( PCR ) CML chronic phase</keyword>
	<keyword>Ponatinib</keyword>
	<keyword>AP24534</keyword>
</DOC>